Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinovac COVID-19 booster safety and immunogenicity in people with HIV
ChiCTR2200058989Phase 4Completed
- Sponsor
- Peking University Shenzhen Hospital
- Start
- Oct 2021
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of coronavac in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Peking University Shenzhen Hospital. Primary endpoints: Rate of adverse effect, Total antibody and 4 more. Started Oct 2021; status: completed.
02
Drugs
coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200058989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058989.